Background: Acquired C l -inhibitor (C l -inh) deficiency is usually associated with the presence of circu-
Introduction
During activation of the serum complement system, complement component Ci binds to immune complexes or other complement activators. Binding of C l to a target results in activation of the complement serine proteases Cl r and C Is, which are subunits of the Cl complex. C Is subsequently cleaves complement Clr or Ci s attacks Ci -inh between residues R444 and T445 and appears to form a stable (covalent) enzyme-pseudosubstrate complex. The tetrametric C l -inh-C lr-C Is-C l -inh complex then dissociates from the Ci complex leaving Clq bound to the complement-activating particle (4) . Like other serpins, Ci -inh forms a stable complex with the proteases it inhibits. The serpin-protease complexes do not dissociate in SDS-PAGE analysis. The precise mode of interaction of serpins and proteases is not fully established (5) , but it is assumed that the protease attacks the serpin as if it were a substrate. Secondary interactions then stabilize the enzymepseudosubstrate complex. The cleavage of the pseudosubstrate can be driven to completion in nonphysiological conditions, such as high pH.
C l -inh deficiency is manifest clinically as angioedema (AE) and may be inherited (HAE) or acquired (AAE). Two types of AAE have been described. Type I is associated with an anti-idiotypic response to plasma or membrane immunoglobulin and occurs in patients with multiple myeloma, chronic lymphocytic leukemia, or benign monoclonal gammopathy (6) . The binding of the anti-idiotype to antibody appears to cause excessive C 1 activation with consumption of C4 and C2 (6) . Excessive catabolism of Ci -inh results in low serum levels of this protein (6) . In type II AAE, autoantibodies to Ci -inh are present (7) and serum Cl -inh levels as judged by immunoassays are normal or only slightly reduced, but it circulates as a cleaved, functionally inactive form (8) which has an apparent Mr of 96 kDa on SDS-PAGE. In our previous study (9), we described 6 patients with type II AAE. The autoantibodies were clonally restricted and recognized an epitope C-terminal to the reactive site residue (R444); the epitope was centered on the sequence QQPF (residues 452-455). The possibility that these antibodies recognized a second, structurally similar epitope (LLVF, residues 446-449) was also noted. In this report we studied the mechanism of action of two of these autoantibodies and show that both prevent the formation of a stable Cls-Cl-inh complex, although they still permit cleavage of Cl-inh by Cls at the reactive site (P1) residue.
Materials and Methods
Patients Two patients (Patients 1 and 2; see Table I in ref. 9 ) with type II AAE were studied. Both patients had immunoglobulin (Ig)G kappa anti-Cl-inh autoantibodies in their sera. The clinical details and the characteristics of the antibodies are described by He et al. (9 Normal and patients sera (10 ml) were incubated with 5 ml protein G Sepharose (Pharmacia, Milton Keynes, U.K.) at 4°C on a rotating stirrer. After 30 min, the mixture was poured into a 15-ml column and the nonadsorbed protein washed through with phosphate-buffered saline (PBS) (pH 7.4) until the absorbance at 280 nm was 0.002. The column was eluted using 100 mM glycine-HCl, pH 2.9, and fractions containing protein were adjusted to pH 7.4 by addition of 2 M Tris-HCl buffer (pH 8.0) prior to dialysis against PBS (pH 7.4).
Affinity Purification of Anti-Cl -Inhibitor Autoantibodies Human Cl-inh (5 mg in 2 ml PBS) was mixed with 2 ml cyanogen bromide-activated Sepharose (Pharmacia) according to the manufacturer's instructions. The coupling efficiency was 83%. IgG (5.0 mg) purified from patient's serum was incubated with 1 ml of Cl -inh-Sepharose at 4°C on a rotating stirrer for 30 min. The mixture was poured into a column, the gel washed extensively with PBS to remove nonspecifically bound IgG molecules, and then washed with 4 column volumes of water. The bound anti-Clinh autoantibody was eluted with 3 M MgCl2.
The eluted protein was dialyzed against PBS prior to use. The concentration of IgG was determined spectrophotometrically using an extinction coefficient (OD280 1 mg/ml, 1 cm = 1.4) (10). Between 0.07 and 0.1 mg of anti-Cl-inhibitor autoantibody could be purified from 5.0 mg total IgG. These antibody preparations contained only IgG as shown by SDS-PAGE, and they bound to solid-phase Cl-inh but not to bovine serum albumin (BSA). Binding to solid-phase C I -inh was inhibited by fluid-phase Cl -inh.
Purification of Cl -Inhibitor and Cls and Radiolabeling Cl -inh was purified from fresh human plasma using the method of Pilatte et al. (11) . Activated Cl s was purified using the method of Sim (12) . SDS-PAGE analysis using 7.5% gels run under nonreducing conditions showed that C 1 -inh had an apparent molecular weight of 115 kDa with a minor band at 96 kDa, whereas under reducing conditions, Cl-inh appeared as a single band of 105 kDa. Under reducing conditions, Cls appeared as two bands of 58 kDa and 27 kDa, whereas under nonreducing conditions, it appeared as a single band of 85 kDa. Concentrations of Cl-inh and Cls were determined using extinction coefficients (OD280, 1 mg/ml, 1cm) of 0.36 for Cl-inh (13) and 0.95 for Cls (14) . For the calculation of molar concentrations of Clinh and Cls, values of 105 kDa and 85 kDa, respectively, were used.
C ls was radiolabeled with Na125I (Amer- sham International, Little Chalfont, U.K.) using lodobeads (Pierce and Warriner, Chester, Cheshire, U.K.) (15) . Free iodide was separated from the labeled protein by gel filtration on a PD-10 (Sephadex G-25) column (Pharmacia).
The specific activity of '25I-labeled C ls was 127,000 cpm/,ug. SDS-PAGE, Autoradiography, and Western Blotting Gels of 10% and 7.5 % w/v acrylamide were used according to the method of Laemmli (16 Effect of Anti-Cl-inh Autoantibodies on Reaction between Cls and Cl-inh Cl -inh, C Is, and autoantibodies were diluted in PBS prior to their addition to reaction mixtures. Reactions were carried out in PBS containing 1 % (v/v) Triton X 100 at 370C for 2 hr. Full details of each reaction are given in the figure legends.
Kinetic Assays
Inhibition of C is activity by Cl -inh was determined by the method of Sim and Reboul (19) with minor modifications. Briefly, Cls, Cl-inh, and autoantibodies were dialyzed against 10 mM Tris-HCl, pH 8.0, containing 100 mM NaCl and 1 mM EDTA. The chromogen, propionyl L-lysyl Incubation of unlabeled C -inh with '251-labeled Cls resulted in the formation of the Cls-Cl-inh complex (Fig. IA) . When anti-Cl -inh autoantibody was preincubated with Cl-inh prior to the addition of '251-labeled Cls, the Cls-C1-inh complex was not seen. As a control experiment, C Is was incubated with the two anti-Cl -inh autoantibodies without Cl -inh. This had no effect on the appearance of C ls in SDS-PAGE analysis. The effect of the autoantibodies on Cl-inh-Cls interaction was dose-dependent and for total inhibition of Cls-Cl-inh complex formation, approximately equimolar concentrations of autoantibody antigen binding sites and Cl-inh were required (Fig. IB) . Normal IgG did not influence the formation of the Cls-Cl-inh complex (Fig. 1B) .
Incubation of peptides 2 or 3 with the autoantibodies prior to their incubation with Cl-inh blocked the effect of the autoantibodies as shown by the formation of the Cls-Cl-inh complex. Peptide 1 had no effect on the activity of the autoantibodies (Fig. 2) .
Effect of Anti-Cl-inh Autoantibodies on Stability of Cls-Cl-inh Complex When anti-Cl -inh autoantibody was added after the incubation (2 hr at 370C) of '25I-labeled Cls with Cl-inh, the Cls-Cl-inh complex was detected (Fig. 3) . Prolonged incubation (up to 16 hr at 37°C) of the Cls-Cl-inh complex with anti-C l -inh autoantibodies did not result in dissociation of the complex. During a 6-hr incubation at 37°C, the presence of a 10-fold molar excess of autoantibody reactive sites over Cl-inh did not result in dissociation of the Cls-Cl-inh complex (data not shown).
Effect of Anti-Cl-inh Autoantibodies on Cleavage of Cl-inh by Cls A 50% inhibitory amount of autoantibody was incubated with Cl-inh for 2 hr at 370C. Following the addition of different concentrations of C ls, the tubes were incubated at 370C for a further 3 hr. The reaction products were separated by SDS-PAGE and then blotted onto nitrocellulose, Cl-inh was detected by sequential incubations with primary antibody, goat anti-human C 1 -inh, secondary antibody, and rabbit anti-goat IgG conjugated with horse-radish peroxidase, followed by detection using the ECL system. In the presence of either autoantibody, the intensity of the 96 kDa band (cleaved form) increased whereas the intensity of the 1 15 kDa band (uncleaved form) decreased with increasing concentration of C ls (Fig. 4A) . A small proportion (approximately 10%) of the purified Cl -inh was in the cleaved form. This may be due to cleavage by C ls or possibly another protease during purification. Scanning densitometry of the Western blot showed that as the C ls concentration increased, the intensity of the 96 kDa band increased (Fig. 4D) (Fig. 4C) . Other bands were not seen. These results were confirmed using two anti-C 1 -inh autoantibodies and the sizes of the fragments were confirmed using three sets of protein markers (Sigma C3187, C3312, and SDS-7). The 52 and 25 kDa bands were much fainter than the 96 kDa band, indicating that only a small proportion of 96 kDa band was further cleaved (Fig. 4C ). This extra cleavage reaction could be Cl s-mediated at R219/T222, which would generate polypeptides of the correct size and disulphide linkage, or it could be due to cleavage with a second protease contaminating one of the reagents. In this regard, there is no plasmin cleavage site that would generate fragments of this size (plasmin cleaves at KG [194] [195] stopped by addition of sample buffer and samples were separated by SDS-PAGE (7.5% w/v polyacrylamide). Proteins were transferred to nitrocellulose by blotting and detected by goat anti-human C l-inh and rabbit anti-goat IgG conjugated with horse radish peroxidase. Cl -inh was detected using ECL reagents and the result is shown. The observed bands are: >190 kDa, Cls-C1-inh complex; 115 kDa, intact Cl -inh; 96 Western blot from nonreducing SDS-PAGE. The concentrations of C 1 -inh and autoantibody were 2.1 ,uM and 1.3 ,uM, respectively, and that of C Is was 8.8 ,M in a total reaction volume of 40 ,l. The reexperiments) (Fig. SA) . These ratios of Cls:Clinh are consistent with a reaction in which 100% inhibition of Cls is produced by an equimolar concentration of C1-inh; i.e., 11.8 nM Cis is inhibited by 12 Fig. 4A . As the concentration of Cls increased, the intensity (area under the curve) of the 115 kDa band of native Cl-inh decreased, while that of the 96 kDa band (cleaved Cl-inh) continued to increase. The intensity of the 190 kDa band (Cls-Cl-inh complex) increased to reach a plateau level when the Cls concentration was approximately 1 ,uM. The density of the 190 kDa band may be an underestimate of the amount of C Is-C 1 -inh complex formed because of the possibility of inefficient transfer of higher molecular weight species from gel to membrane.
tions of CIs and CI-inh of 23.5 nM and 12.7 nM, respectively, we determined that the autoantibody concentration that resulted in total loss of C I -inh activity was 13 nM (26 nM antigen binding sites) in the reaction volume of 3 ml ( Cl-inh deficiency could also result from a mechanism that permits enzymatic cleavage of Cl-inh by Cls but prevents formation of the stable enzyme-inhibitor complex, thus converting C l -inh to a substrate. Mutations in the proximal hinge region of C l -inh, A434E (24) , V432E, and A434T (25) , convert Cl-inh to a substrate for Cls. The mutant Cl-inh species are cleaved to forms with a molecular weight of 96 kDa. The data presented here suggest that the Cl -inh autoantibodies studies produce Cl -inh deficiency by such a mechanism. However, these autoantibodies recognize the epitope QQPF and/or LLVF, both of which are C-terminal to the R444 reactive site residue (9) .
The first set of experiments, using '25I-labeled Cls, showed that although the autoantibodies prevented the formation of a stable enzyme-inhibitor complex, they were unable to dissociate the complex, even with a large (10-fold) molar excess of autoantibody. Thus Ci -inh autoantibodies must act prior to the formation of the enzyme-inhibitor complex.
In the second set of experiments, incubation of Cl -inh with autoantibodies prior to exposure to Cls resulted in cleavage of Cl-inh, with the production of the 96 kDa form and the failure to form a Cls-Cl-inh complex. These two sets of experiments show that in the presence of the autoantibodies, C is is able to cleave Cl -inh, probably between the reactive site residue (R444) and T445. This cleavage is not followed by the formation of a stable enzyme-inhibitor complex. Thus Cl-inh inhibitory activity is lost and Cls maintains its active form after it dissociates from cleaved form Cl-inh-Cls complex.
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The effect of autoantibodies in 'converting" Clinhibitor from an inhibitor to a substrate is entirely consistent with previous findings (26) . The site of interaction of autoantibody with Cl-inh has now been clarified (9), permitting more detailed analysis of the mechanism.
The dose-response studies using 125I-labeled Cls and the data from kinetic assays show that for complete abrogation of Cl -inh activity, equimolar concentrations of autoantibody and Cl-inh were required. Interestingly, the serum molar concentrations of the two autoantibodies studies were similar to those of Cl -inh (9) . There are at least three explanations as to why anti-Clinh autoantibodies result in the production of cleaved inactive Cl -inh. The possibility that the autoantibodies themselves have enzymatic activity was excluded by the demonstration that cleavage of Cl -inh only occurred when CIs was present in addition to the autoantibody (Figs. 3 and 4). It is also possible that the binding of the anti-Cl-inh autoantibody produces a conformational change in C l -inh, which makes it susceptible to proteolysis by enzymes other than those which it usually regulates. Although we have no direct evidence to show that this does not occur in vivo, the observations that the 96 kDa cleaved form of C l -inh circulates in vivo and is generated from the incubation of Cl-inh, anti-Cl-inh autoantibody, and Cls in vitro suggest that this is not the case. Our data support the view that the binding of anti-Cl-inh autoantibody to Cl-inh converts C 1 -inh from a pseudosubstrate to a substrate. As a result of the autoantibody being bound to C l -inh, the bond formed between S195 of Cls and R444 of Cl-inh is destroyed, probably because the bond is attacked by reactive small molecules in the solvent, i.e., by hydrolysis. In other experiments (27) , we have shown that Cls, like anti-Cl-inh autoantibodies, binds to peptide 3, which suggests that the distal hinge region of Cl -inh contains a secondary binding site for C is. We hypothesize that the interaction of C Is with this secondary binding site is essential for the formation of a stable C Is-Cl -inh complex. Binding of the autoantibody to C 1 -inh would prevent the interaction of C Is with the secondary binding site and expose the bonding atoms to the solvent, resulting in their hydrolysis so that a stable complex does not form. The observation that even with a 4-fold molar excess of C Is over Cl -inh, the latter was not completely incorporated into the SDS-stable enzyme-inhibitor complex, suggests that a proportion of the Cl-inh preparation was in a conformationally altered form. However, complete cleavage of Cl -inh occurred while Cl -inh autoantibody was preincubated with Cl -inh, which suggests that the autoantibody can also produce a conformational change in Cl -inh, rendering it susceptible to proteolysis by Ci s. An alternative explanation is that a proportion of the Cls-Clinh complexes formed are reversible and that the autoantibody drives the reaction to the stage at which it is irreversible.
The observation that peptides 2 and 3, but not peptide 1, inhibited the effect of the autoantibody on Cls-Cl-inh complex formation confirms our previous conclusion (8) that both peptides 2 and 3 contain an epitope recognized by the autoantibody. Furthermore, they suggest that both of these peptides might have therapeutic value in the management of patients with AAE with Cl -inh autoantibodies of the specificity of those described in this study. Our original report described six patients; since then, we have diagnosed a further six, all of whom have autoantibodies that react strongly with peptide 3 and to a lesser extent, with peptide 2, suggesting that this specificity is common to type II AAE.
